

	STANDALONE UNAUDITED FINANCIAL RESULT	S FOR THE QUAR	TER/NINE MO	NTHS ENDED O	N 31 DECEMBE		
PART I	Particulare		O F., d. d				In Million INR
Sr.No.	Particulars	31/12/2014	Quarter Ended 30/09/2014	31/12/2013	Nine Mon 31/12/2014	31/12/2013	Year Ended 31/03/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Manufacturing Sales Trading Sales	193.39 15.75	196.77 18.12	144.12 14.51	607.64 49.43	435.62 36.39	638.34 52.14
	Other Operational Income	9.69	0.00	0.00	9.69	0.00	0.00
	Net Sales/ Income from Operations	218.83	214.90	158.62	666.76	472.01	690.48
2	Total Expenses	164.06	168.33	124.81	500.87	354.06	490.96
	(a) Cost of material consumed	46.45	39.36	22.93	118.36	69.96	104.56
	(b) Purchases of Stock in Trade	7.91	14.00	9.13	31.59	29.20	39.28
	(c) Change in inventories (d) Employee benefits Expenses	14.60 29.20	15.85 26.31	-5.44 18.86	59.51 82.45	-19.85 66.84	-30.32 98.37
	(e) Depreciation	8.53	8.53	16.30	25.34	38.38	53.78
	(f) Other Expenses - mfg.exp.	30.31	36.83	36.24	95.33	93.27	116.49
	(g) Other Expenses - Selling, Admn.	27.07	27.45	26.79	88.30	76.25	108.80
3	Profit From Operations before other income, finance cost,& exceptional items.	54.77	46.57	33.81	165.90	117.95	199.52
4	Other Income	0.22	0.17	0.86	0.55	1.42	7.73
5	Profit from ordinary activities before finance	54.99	46.74	34.67	166.45	119.37	207.25
	costs & exceptional items						
6	Finance Cost	9.62	10.91	9.20	30.22	28.52	64.34
7	Puelit from endinger activities often finance	45.36	35.83	25.47	136.23	90.85	142.91
,	Profit from ordinary activities after finance cost but before exceptional items	43.30	33.63	23.47	130.23	90.03	142.91
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit from ordinary activities before tax	45.36	35.83	25.47	136.23	90.85	142.91
10	Tax Expense	11.65	8.40	0.03	31.68	29.12	42.03
10	Tax Expense	11.03	0.40	0.03	31.00	29.12	72.00
11	Net Profit from ordinary activities after tax	33.71	27.43	25.45	104.55	61.73	100.88
12	Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
42	Not Built footh a Built d	22.74	27.42	25.45	404.55	64.70	400.00
13	Net Profit for the Period	33.71	27.43	25.45	104.55	61.73	100.88
14	Paid-up equity share capital (face value of INR 10)	85.07	85.07	85.07	85.07	85.07	85.07
15	Reserves & Surplus	0.00	0	0	0.00	0	674.65
16	EPS (INR) (not annualised)(before and after extraordinary items)	3.96	3.22	2.99	12.29	7.26	11.86
PART I							
	PARTICULARS OF SHARE HOLDING Public shareholding:						
1	- Number of Share	3929028	3929028	3962116	3929028	3962116	3962116
	- % of Shareholding	46.19	46.19	46.58	46.19	46.58	46.58
2	Promoters and Promoter group shareholding						
a)	Pledged / Encumbered						
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Ni
	- percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Ni
	- Percentage of shares (as a % of the total						.,,
LX	share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Ni
b)	Non- encumbered - Number of shares	4577772	4577772	4544684	4577772	4544684	4544684
	- percentage of shares (as a % of the total	.57,7,72	.5////2	.511001	2	.511001	.51100
	shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total		F0.0:	E0 :-		E0 :-	E0 :-
В	share capital of the Company) INVESTOR COMPLAINTS	53.81	53.81 Qua	53.42 rter ended on 31	53.81 st December, 20	53.42 14	53.42
	Pending at the beginning of the quarter	NIL					
	Received during the quarter			1			
	Disposed of during the quarter	1 NIL					

HESTER BIOSCIENCES LIMITED

Pushpak, Level One, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat 380006, India Phone +91 79 2644 5107 Fax +91 79 2644 5105 Email mail@hester.in Web www.hester.in CIN L99999GJ1987PLC022333



	REPORT ON SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED							
	Particulars	Quarter Ended			Nine Months Ended		Year Ended	
Sr. No.		31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Segment Revenue							
	a. Poultry Vaccine	205.06	198.93	145.59	623.38	439.99	644.93	
	b. Large Animal Health Product	13.77	15.97	13.04	43.38	32.02	45.55	
	Total Income from Operations(Net)	218.83	214.90	158.62	666.76	472.01	690.48	
2	Segment Results (Profit before Finance Cost, Exceptional Items							
	and Taxes)							
	a. Poultry Vaccine	56.56	47.33	35.53	171.23	129.64	221.47	
	b. Large Animal Health Product	-1.58	-0.61	-0.86	-4.78	-10.26	-14.22	
	Total	54.98	46.73	34.67	166.45	119.37	207.25	
	a. Finance Costs	9.62	10.91	9.20	30.22	28.52	64.34	
	b. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	
	c. Other unallocable expenditure/(income) [Net]	0.00	0.00	0.00	0.00	0.00	0.00	
	Profit before Tax	45.36	35.82	25.47	136.23	90.85	142.91	
3	Segment Capital Employed							
	a. Poultry Vaccine	783.26	694.79	686.41	783.26	686.41	729.30	
	b. Large Animal Health Product	52.34	48.37	271.30	52.34	271.30	39.52	
	c. Unallocated Capital Employed	0.00	72.14	37.28	,	37.28	40.17	
	Total	835.60	815.30	994.99	835.60	994.99	808.99	

Notes:

- The Board of Directors have approved the aforesaid working result at their meeting held on 21st January, 2015 after reviewed by the Audit Committee of the Company.
- 2 Segment wise reporting as defined in Accounting Standard (AS-17) is given seperately.
- Segment wise reporting as defined in Accounting Standard (As-17) is given seperately.

 Provision for traxation includes Current Tax of INR 31.68 million including deferred Tax Expense of INR 3.13 million for the nine months ended as per AS-22.

 Effective 1st April 2014 depreciation and amortization for the 9 months ended on 31st December 2014 has been calculated in accordance with Schedule II of the Companies Act, 2013.

 Consequently depreciation and amortization for the 9 months ended on 31st December 2014 is lower by INR 16.20 million and opening balance of General Reserve is reduced by INR 9.60 million. Under the circumstances, Depreciation and Amortization for the 9 months ended on 31st December 2014 is not comparable with the same for corresponding year, which was calculated as per the provisions of the Companies Act, 1956.
- The Auditors of the Company have carried out a "Limited Review" for the said Financial Results.
- During the quarter, Company has acquired 100% share holding of Gujarat Agrofarm Limited at INR 5.25 million, thereby formed new Wholly Owned Subsidiary Company.
- The figures have been re-grouped / rearranged wherever necessary.

By order of the Board

Rajiv Gandhi CEO & Managing Director

Place: Ahmedabad Date: 21.01.2015

HESTER BIOSCIENCES LIMITED